Shares of Epizyme Inc. (NASDAQ:EPZM) fell 4.5% on Wednesday . The stock traded as low as $9.96 and last traded at $10.08, with a volume of 109,975 shares. The stock had previously closed at $10.55.

Several brokerages recently weighed in on EPZM. Zacks Investment Research cut shares of Epizyme from a “buy” rating to a “sell” rating in a research note on Tuesday. JMP Securities reissued a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research note on Thursday, June 23rd. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Finally, Leerink Swann reissued an “outperform” rating and issued a $39.00 price objective on shares of Epizyme in a research note on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Epizyme presently has an average rating of “Buy” and an average price target of $23.11.

The company’s market cap is $571.65 million. The firm’s 50-day moving average is $11.00 and its 200 day moving average is $10.79.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Equities research analysts forecast that Epizyme Inc. will post ($2.25) EPS for the current fiscal year.

In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $10.03, for a total value of $40,120.00. Following the transaction, the insider now owns 4,000 shares in the company, valued at approximately $40,120. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

A number of institutional investors have modified their holdings of EPZM. Jennison Associates boosted its position in shares of Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares during the last quarter. California Public Employees Retirement System acquired a new position in shares of Epizyme during the fourth quarter worth approximately $2,723,000. Finally, Jennison Associates LLC boosted its position in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares during the last quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.